image description

*Data presented refer to treatment with once-daily SPIRIVA® 18 μg via HandiHaler® or SPIRIVA® Respimat® 2.5 μg (two puffs, once daily).

References
1. Boehringer Ingelheim GmbH, data on file. 2. IMS Health Data, Q4 2015. 3. National Institutes of Health. http://clinicaltrials.gov/ct2/results?term=tiotropium+COPD&Search=Search. Accessed March 23, 2016. 4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; Updated 2016. www.goldcopd.org. Accessed January 5, 2016.